Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 9% – Should You Buy?

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) shot up 9% during mid-day trading on Thursday . The stock traded as high as $7.13 and last traded at $7.1050. Approximately 47,569 shares traded hands during mid-day trading, a decline of 50% from the average daily volume of 95,853 shares. The stock had previously closed at $6.52.

Wall Street Analysts Forecast Growth

A number of analysts have commented on GYRE shares. Zacks Research cut shares of Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, March 16th. Weiss Ratings cut Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 11th. Finally, Wall Street Zen downgraded shares of Gyre Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Gyre Therapeutics currently has an average rating of “Hold” and a consensus target price of $17.00.

Gyre Therapeutics Stock Up 9.4%

The company has a market capitalization of $794.92 million, a PE ratio of -79.24 and a beta of 1.90. The firm’s 50 day simple moving average is $6.55 and its 200 day simple moving average is $7.26.

Insider Buying and Selling

In related news, CEO Ying Luo sold 10,136 shares of the firm’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $8.04, for a total value of $81,493.44. Following the transaction, the chief executive officer owned 2,565,226 shares of the company’s stock, valued at $20,624,417.04. This trade represents a 0.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Weiguo Ye sold 12,820 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $6.15, for a total transaction of $78,843.00. Following the transaction, the chief operating officer directly owned 700,000 shares in the company, valued at approximately $4,305,000. This trade represents a 1.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 32,535 shares of company stock worth $219,580. Insiders own 9.50% of the company’s stock.

Institutional Trading of Gyre Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its position in shares of Gyre Therapeutics by 28.6% in the 2nd quarter. Geode Capital Management LLC now owns 401,709 shares of the company’s stock worth $2,953,000 after purchasing an additional 89,390 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Gyre Therapeutics by 37.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock valued at $1,194,000 after purchasing an additional 45,772 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Gyre Therapeutics in the 3rd quarter valued at $267,000. State Street Corp increased its holdings in Gyre Therapeutics by 10.7% in the 4th quarter. State Street Corp now owns 202,225 shares of the company’s stock worth $1,428,000 after buying an additional 19,472 shares during the period. Finally, Lazard Asset Management LLC purchased a new position in shares of Gyre Therapeutics during the third quarter worth $111,000. 23.99% of the stock is owned by hedge funds and other institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.